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Iron is an essential mineral needed for normal physiologic processes. While its function
in oxygen transport and other important physiologic processes is well known, less is
understood about its role in inﬂammatory diseases such as atherosclerosis. Existing
paradigms suggest iron as a driver of atherosclerosis through its actions as a pro-oxidant
capable of causing lipid oxidation and tissue damage. Recently we and others have
identiﬁed hemoglobin (Hb) derived iron as an important factor in determining macrophage
differentiation and function in areas of intraplaque hemorrhage within human atheroscle-
rosis. Hb associated macrophages, M(Hb), are distinct from traditional macrophage foam
cells because they do not contain large amounts of lipid or inﬂammatory cytokines, are
characterized by high levels of expression of mannose receptor (CD206) and CD163 in
addition to producing anti-inﬂammatory cytokines such as IL-10. Despite the well-known
role of iron as an catalyst capable of producing lipid peroxidation through generation of
reactive oxygen species (ROS) such as hydroxyl radical, we and others have shown that
macrophages in areas of intraplaque hemorrhage demonstrate reduced intracellular iron
andROSwhich triggers production of anti-inﬂammatory cytokines aswell as genes involved
in cholesterol efﬂux. These data suggest that manipulation of macrophage iron itself may
be a promising pharmacologic target for atherosclerosis prevention through its effects on
macrophage inﬂammation and lipid metabolism. In this review we will summarize the
current understanding of iron as it relates to plaque inﬂammation and discuss how further
exploration of this subject may lead to new therapies for atherosclerosis.
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IRON IN THE VASCULATURE
Iron is a powerful catalyst resulting in the production of a hydroxyl
radical through the oxidation of its ferrous (Fe2+) to ferric form
(Fe3+) through the Fenton reaction (Crichton et al., 2002). In
the endothelium, heme-derived iron is thought to catalyze oxi-
dation of low density lipoproteins by itself or in conjunction
with myeloperoxidase or lipoxygenase located on the endothe-
lial surface (Balla et al., 1991; Miller et al., 1997; Camejo et al.,
1998; Jeney et al., 2002; Yoshida and Kisugi, 2010). Hemoly-
sis is often a result between the interaction of erythrocytes and
mature atheromas resulting in the transition of ferrous to fer-
ric forms of hemoglobin (Hb) which additionally leads to lipid
oxidation (Nagy et al., 2010). Furthermore this oxidized form of
Hb can also act as a pro-inﬂammatory agonist targeting vascu-
lar endothelial cells (Silva et al., 2009). Ferritin, a hepatic protein,
may counteract some redox activity via ferroperioxidase in the
vasculature (Balla et al., 1992), however, overall oxidation can be
largely unchecked in these distinct pathologic environments as
intraplaque hemorrhage. Oxidized low density lipoproteins (LDL)
have a high afﬁnity for the LDL receptor on macrophages leading
their development into foam cells. Foam cells provide the major
inﬂammatory component of atherosclerotic plaques. Foam cells
density and necrotic core size within atherosclerotic plaques is
thought to be a key determinant of plaque vulnerability for rupture
(Sakakura et al., 2013). While the role of iron as a pro-oxidant has
been established in vitro (Smith et al., 1992; Juckett et al., 1995;
Pang et al., 1996; Silva et al., 2009), there is not a clear association
of increased serum iron and increased incidence of coronary artery
disease (CAD; Miller and Hutchins, 1994). In disease states of
iron overload, such as hemochromatosis, an autopsy study found
the extent of CAD to be less than the general population while
another prospective study of 9000 individuals found carriers of
the hemochromatosis genotypes C282Y to not have an increased
risk for ischemic heart disease or myocardial infarction (Miller
and Hutchins, 1994; Ellervik et al., 2005). Furthermore, dietary
iron overload in Apo E−/− mice reduces rather than exacerbates
the severity of atherosclerosis (Kirk et al., 2001). These experi-
mental data challenge the prevailing idea of iron as a pro-oxidant
capable of accelerating coronary artery disease.
SYSTEMIC IRON REGULATION AND LINKS TO
INFLAMMATION
Themajority of iron needed to regulate normal bodily functions is
recycled from senescent red cells by the reticuloendothelial system.
Additional demand for iron due to various environmental chal-
lenges such as anemia is ﬁne-tuned by adjusting iron absorption
via enterocytes. In some disease states, such as hemochromato-
sis, the regulation of iron is disturbed leading to excess iron
entering the body. There are many systems within body that reg-
ulate the balance of iron. For the purposes of this review, we
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will focus on those within the macrophage. The regulation of
movement of iron through various organs in the body is critical
to maintaining iron homeostasis. Ferroportin (FPN), a trans-
porter which mediates exit of iron from macrophages into the
circulation, is an extremely important mechanism for immedi-
ate control of available and circulating serum iron. Although
regulated at multiple levels, the peptide hormone, hepcidin, is
the key regulator of FPN. Hepcidin binds to FPN inducing its
internalization and degradation (Nemeth et al., 2004). Hepcidin
induced downregulation of FPN thus inhibits cellular iron export
from macrophages. The hepcidin-FPN axis is a major regula-
tory mechanism that maintains iron homeostasis in response
to changing requirements. Also known as an acute phase reac-
tant, hepcidin responds to inﬂammation resulting in adjustments
to FPN levels which alters the regulation of body iron status
(Ganz, 2003). The importance of this mechanism is observed
in hereditary hemochromatosis where often either the expression
or function of hepcidin is disturbed. In these situations, FPN
is elevated because of low circulating hepcidin levels leading to
increased gut iron absorption and pathologic deposition of iron
in tissues.
Interestingly, mice deﬁcient in the hemochromatosis gene,
Hfe, have attenuated inﬂammatory responses to bacterial chal-
lenge associated with decreased macrophage TNF-α and IL-6
after exposure to the canonical Toll-like receptor 4 agonist
lipopolysaccheride (LPS). These data suggest that these animals
have impairment in Toll-like receptor 4 (TLR4) signaling (Wang
et al., 2009). These defects could be replicated by exposing wild
type murine macrophages to iron chelators, suggesting low intra-
cellular iron within Hfe KO macrophage may lead to impaired
TLR4 signaling. Thus, these results suggest iron overload in the
setting of hemochromatosis may be associated with dampening of
inﬂammation rather than exacerbating it.
LOCAL IRON REGULATION BY MACROPHAGES AND LINKS
TO ANTI-INFLAMMATION
In addition to helping to maintain systemic iron homeostasis,
macrophages are intimately involved in preventing toxic effects
of iron release during events involving hemolysis including in
the setting of intraplaque hemorrhage. We and others have pre-
viously shown the importance of intraplaque hemorrhage, an
event which leads to the deposition of erythrocyte-derived iron, in
humanatherosclerotic lesions (Kolodgie et al., 2003). In a relatively
large number of human coronary plaques from sudden coro-
nary death victims, we observed a greater frequency of previous
intraplaque hemorrhages in plaques prone to rupture compared
to early lesion morphologies or stable plaques. Hemorrhage itself
contributes to the deposition of free cholesterol and enlargement
of the necrotic core in atherosclerotic plaques through the accu-
mulation of erythrocyte membranes that are rich in cholesterol.
These ﬁndings were paralleled by an increase in macrophage den-
sity, which supports previous observations that hemorrhage itself
is an inﬂammatory stimulus.
During hemorrhage, the pro-oxidant environment of
atherosclerosis promotes erythrocyte lysis and accumulation of
free Hb, which, if not eliminated, may cause tissue damage
by releasing free iron which increases oxidative stress through
the Fenton reaction. During hemolysis, free Hb binds to the
plasma protein haptoglobin and hemoglobin:haptoglobin (HH)
complexes are formed. CD163, the receptor for this complex, is
expressed exclusively on the surface of macrophages and binds
to HH, mediating its endocytosis. Conversely the interaction of
haptoglobin itself with CD163 is impaired in highly oxidized
environment (Vallelian et al., 2008), suggesting a more favorable
interaction in the form of HH complexes. The heme subunit of
Hb is then degraded by the heme oxygenase (HO-1) enzymes. The
HO-1 pathway, which produces anti-oxidants carbon monoxide
and biliverdin also releases free iron (Fe2+). Once iron has been
released by HO-1, it is either utilized by the cell, stored as ferritin
in a redox inactive form, or exported via FPN and converted to less
redox active ferric iron (Fe3+) via ceruloplasm. Although the role
of HO-1 in atherosclerosis has been studied in detail, an exact
understanding of the molecular events in macrophages which
orchestrate responses to iron and how this affects macrophage
function remains incompletely understood. In addition, because
hemorrhage, iron, andmacrophages are not infrequently found in
advanced atherosclerosis, the ﬁndings of these studies have impor-
tant implications for our understanding of how iron itself event
inﬂuences this disease.
The macrophage is the major inﬂammatory cell involved in
atherosclerosis progression (Libby, 1995; Ross, 1999). While the
role of lipid-rich foam cell macrophages which up-regulate pro-
teolytic enzymes leading to plaque rupture has been extensively
studied, less attention has been paid to alternative macrophage
phenotypes which exist in atherosclerosis (Libby, 1995). It has
been classically thought that macrophages exist in two subtypes:
(1)“classically”activated (M1)macrophages, which are induced by
Th1 cytokines such as tumor necrosis factor α (TNF-α) and LPS,
and (2) alternative M2 cells, stimulated by Th2 cytokines such as
IL-4 or IL-13 which produce anti-inﬂammatory cytokines such as
IL-10 (Gordon, 2003).
Studies done by Boyle et al. (2009), in addition to our lab, sug-
gest a third macrophage phenotype [M(Hb) or Mhem], induced
by ingestion of HH complexes leading to an anti-inﬂammatory
effect via production of anti-inﬂammatory cytokines such as IL-
10 and production of anti-inﬂammatory metabolites produced
during heme metabolism (Boyle et al., 2009; Finn et al., 2012).
CD 163, INTRAPLAQUE HEMORRHAGE, AND MACROPHAGE
POLARIZATION
Boyle et al. (2009, 2011) were the ﬁrst to explore the effects of
intraplaque hemorrhage on macrophage phenotype. Advanced
atherosclerotic plaques were examined for immunostaining
for CD163 and HLA-DR, a sign of macrophage activation.
Macrophages were found to express either CD163 or HLA-DR.
The CD163high macrophages were found in areas of intraplaque
hemorrhage and displayed evidence of less oxidative damage. This
phenotype could be reproduced by exposure of human mono-
cytes to HH complexes. More recently, our lab has expanded this
work to demonstrate that macrophages in areas of human coro-
nary intraplaque hemorrhage represent a subtype distinct from
foam cells or the previously reported M2 phenotype.
These cells, characterized by high surface mannose recep-
tor (MR, CD206) and CD163, exhibit reduced expression of
Frontiers in Pharmacology | Drug Metabolism andTransport August 2014 | Volume 5 | Article 195 | 2
Habib and Finn Iron, inﬂammation, and atherosclerosis
pro-inﬂammatory cytokines such as tumor necrosis factor alpha
(TNFα), and are devoid of lipids typical of foamy macrophages
(Figure 1; Finn et al., 2012). The term M(Hb) or Hb associ-
ated macrophages (Mhem) was used to refer to this subset since
induced by ferrous Hb not IL-4 or hemorrhage (Bouhlel et al.,
2007; Boyle et al., 2009). These cells demonstrate a unique iron
handling signature associated with activation of the nuclear recep-
tor liver × receptor alpha (LXRα), upregulation of ferroportin
(FPN) and CD163. The activation of LXRα in addition to HO-
1 was thought to be via oxidative stress from heme release and
phosphorylation of activating transcription factor 1 (ATF-1; Boyle
et al., 2012). Cultured human monocytes exposed to HH com-
plexes have reduced free intracellular iron and reactive oxygen
species (ROS) levels likely due to increased sequestration of iron
by ferritin and by increased export of free iron outside the cell via
FPN. This reduction in free iron and ROS could be reversed by
pre-treating with cells with hepcidin, suggesting the importance
of FPN in this effect. Moreover, M(Hb) macrophage demonstrate
resistance to lipid loading, lowered expression of genes involved in
lipid uptake (i.e., SR-A1, SR-A2, CD36, SR-B1) that characterize
foam cells and increased reverse cholesterol through ATP bind-
ing cassette (ABC) transporters (i.e., ABCA1, ABCG1) involved
in Apo-A1 cholesterol efﬂux to high density lipoproteins (HDL;
Figure 2).
Our work suggests that iron itself does not result in increased
oxidative stress and lipid retention with atherosclerotic plaque
macrophages. Instead areas of hemorrhage demonstrate the oppo-
site ﬁndings with little evidence of oxidative damage as assessed
by 8- hydroxyguanine staining and diminished macrophage foam
cell formation. To demonstrate the causal effect of lowering
intracellular iron in the phenotype of M(Hb) cells, we treated
HH differentiated macrophages with hepcidin and found that
ABCA1 expression was signiﬁcantly reduced. Moreover this was
associated the downregulation of LXRα activity, a major tran-
scriptional driver or ABCA1. This suggests the importance of
macrophage intracellular iron levels driving cholesterol efﬂux in
M(Hb) cells. Additionally differentiation of human macrophages
with anti-oxidants such as superoxide dismutase (SOD) increased
ABC transporter expression suggesting lowered ROS as a ﬁnal
common trigger for increasing cholesterol efﬂux. This suggests
that manipulation of macrophage iron levels via the hepcidin-
FPN axis represents a promising avenue to retard atheroscle-
rosis development via up-regulation of macrophage cholesterol
efﬂux.
FIGURE 1 | Identification of M(Hb) macrophages in an area of
hemorrhage in a human coronary fibroatheroma. (A) Cryosection shows
a ﬁbroatheroma with a necrotic core (NC, arrows). Movat pentachrome
staining. (B–I) represent the area within the black box in “a.” (B) Accumu-
lation of inﬂammatory cells in an area of prior hemorrhage adjacent to the
NC, H&E. (E) Iron (Fe) accumulation near the periphery of the necrotic
core. (D) identiﬁcation of macrophages by CD68 shows strong staining
within the cell cluster adjacent to the necrotic core. (E) Intense staining for
the mannose receptor (MR, CD206) within the cell cluster; note, however,
the adjacent necrotic core shows negative staining. (F) The same MR
positive macrophages within the cluster are also strongly positive for
CD163, while the necrotic core remains negative. (G) Shows that the same
cluster of cells is negative for lipid (ORO) while the adjacent necrotic core
is strongly positive. The area of CD206/CD163 positive macrophages does
not stain for CD36 (H) or TNFα (I). Reproduced from Finn et al. (2012)
permission pending.
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FIGURE 2 | Polarization of hemoglobin-associated macrophage, M(Hb).
Macrophage polarization to the M(Hb) phenotype via exposure to
hemoglobin: haptoglobin (HH) complex involves the increased expression of
CD163, the HH receptor, increased ferroportin-1 (FPN), an iron exporter
resulting in decreased intracellular iron and reactive oxygen species (ROS).
These cells are characterized by decreased inﬂammatory cytokine (i.e., TNF-α)
expression in addition to increased reverse cholesterol transport via ABCA1,
changes which are driven by reduced intracellular iron.
MACROPHAGE DIVERSITY IN HUMAN ATHEROSCLEROSIS –
ROLE OF M(Hb) vs. M2 MACROPHAGES
Recent studies such as those from Chinetti-Gbaguidi et al. (2011)
have looked IL-4 induced M2 macrophages in human atheroscle-
rotic plaques. However, unlike M(Hb) where intraplaque hemor-
rhage provides a precipitant for its differentiation, the source for
driving IL-4 remains unclear. Additionally, IL-4 differentiated M2
macrophages demonstrate mannose upregulation but not CD163
and do not demonstrate the same iron handling signature in that
they show no increase in FPN expression and minimal changes
in HO-1 and ferritin heavy chain (Bories et al., 2013). However,
when M2 macrophages were exposed to iron, both FPN, HO-1,
and LXRα-dependent genes such as ABCA1 were induced, mim-
icking the phenotype of M(Hb) macrophages. These data suggest,
regardless of the stimulus (Hb or less physiologic FeCl3), iron
is an essential factor driving the phenotype found in areas of
intraplaque hemorrhage.
Hemoglobin: haptoglobin differentiated macrophages resist
exogenous lipid loading to a much greater extent compared to
IL-4 differentiated M2 macrophages and are characterized by an
entirely different expression pattern of lipid handling genes (Boyle
et al., 2012). However, M(Hb) demonstrated reduced expres-
sion of the scavenger receptors CD36 and increased expression
of cholesterol efﬂux genes ABCA1/ABCG1, M2 macrophages
demonstrate the opposite pattern with increased CD36 expression
and reduced expressionofABCA1and cholesterol efﬂux (Chinetti-
Gbaguidi et al., 2011). Furthermore, a microarray analysis of 2400
genes showed a distinct gene transcriptome signature of M(Hb)
versus M2 macrophages (Boyle et al., 2012).
Our work suggests that liver x receptor alpha (LXRα), an
inducible transcription factor known to be important in human
macrophage ABC transporter transcription, may play a central
role in the response to heme-derived iron ingestion. LXRα can be
activated by oxysterols which can also be produced by iron load-
ing. The works of Bories et al. (2013) indicates LXRα appears to
direct the upregulation of FPN and the repression of hepcidin,
a protein which inhibits iron transport out of macrophages by
degrading FPN. LXRα is likely a criticalmediator of iron responses
in macrophages especially M(Hb) with roles in lipid handling
and inﬂammatory responses through transcriptional control of
FPN/hepcidin.
HEPCIDIN-FPN AXIS: MODULATION OF MACROPHAGE
DIVERSITY TO IMPROVE ATHEROSCLEROTIC PROGRESSION
Given the link between macrophage the hepcidin→FPN axis,
macrophage intracellular iron and the atheroprotective pheno-
type of M(Hb) we examined the effect of inhibitors of hepcidin
on macrophage lipid metabolism (Yu et al., 2008; Saeed et al.,
2012). Bonemorphogenic protein-1 (BMP-1) signaling is involved
in hepcidin gene transcription via SMAD 1/5/8 phosphorylation
(Yu et al., 2008). BMP-1 inhibitors, such as dorsomorphin, and
LDN, potently inhibit hepcidin production by blocking BMP-1
receptors, ALK 2/3/6 preventing its downstream effects on SMAD
(Boergermann et al., 2010; Saeed et al., 2012). Effects of this
BMP-1 inhibition on macrophage polarization lead to increased
ABCA1/G1 expression, decreased cytokine and ROS production
and increased FPN production (Saeed et al., 2012). These effects
again were mitigated through hepcidin repletion (Saeed et al.,
2012). Interestingly, LDN treatment delayed atherosclerotic pro-
gression in transgenic ApoE knockout mice and increased serum
iron suggesting a potent effect in reducing intracellular iron con-
tent and plaque progression (Saeed et al., 2012). It must be stated,
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however, that inhibitionof BMPsignaling could reduce atheroscle-
rosis via additional mechanisms not explored by us Derwall et al.
(2012). However, the long-term effects of such manipulations
which increase serum and likely tissue iron via up-regulation of
FPN remains unclear. Given the pivotal role of hepcidin in reg-
ulating iron homeostasis, its chronic inhibition could potentially
result in an iron overload-like state, which may limit the actual
clinical adoption of such as strategy.
Further support for our data come from others work which has
shown shown that overexpression of hepcidin both in vitro and in
vivo murine ApoE carotid plaque model increases plaque instabil-
ity especially in the setting of macrophage iron loading (Li et al.,
2012). AdditionallyWang et al. (2009) demonstrated that similarly
targeted inhibitors of BMP signaling signiﬁcantly attenuated infec-
tious and non-infectious enterocolitis in a mouse model, again
reinforcing the anti-inﬂammatory effect of this strategy which
may be mediated in part through TLR4 inhibition (Wang et al.,
2009). Given these ﬁndings, it suggests that the hepcidin-FPN axis
is an important modulator of inﬂammation and determinant of
macrophage polarization.
CONCLUSION
Our knowledge of the effects of iron on inﬂammation and
atherosclerosis continues to evolve. Recent studies on human
atherosclerosis demonstrate that areas of intraplaque hemorrhage
where iron is abundant demonstrate reduced ROS, tissue damage,
lipid retention and inﬂammation. These data challenge existing
paradigms that iron is a catalyst capable of producing ROS which
accelerates atherosclerosis. Our data point to an important role
for LXRα, FPN, hepcidin in controlling macrophage iron levels
and thereby determining these cells lipid handing and inﬂam-
matory potential. These studies suggest that approaches to reduce
intracellularmacrophage iron that involve downregulation of hep-
cidin either directly (i.e., via shRNA) or indirectly (i.e., BMP-1
inhibitors) and may present a therapeutic beneﬁt for advanced
atherosclerotic lesions and perhaps other inﬂammatory condi-
tions. However, given side effects that would occur by interfering
with the FPN/hepcidin axis, more investigation is necessary to
deﬁne this strategy of localmodulation of inﬂammation to prevent
atherosclerosis progression.
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